Comparative Pharmacology
Head-to-head clinical analysis: IRON DEXTRAN versus TRIFERIC AVNU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IRON DEXTRAN versus TRIFERIC AVNU.
IRON DEXTRAN vs TRIFERIC AVNU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron dextran is a colloidal solution of ferric oxyhydroxide complexed with dextran, which provides a source of iron for hemoglobin synthesis. After intramuscular or intravenous administration, the iron-dextran complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
Triferic AVNU (ferric pyrophosphate citrate) is an iron replacement product that provides iron to hemoglobin synthesis without increasing circulating iron levels. It is taken up by transferrin and delivered to erythroid precursor cells for heme synthesis.
IM or IV: Calculate total iron deficit using formula: Body weight (kg) × (target Hb - actual Hb) × 0.24 + 500 mg (for iron stores). Administer as single IV infusion or daily IM doses up to 2 mL (100 mg) per day. IV infusion: Dilute in 0.9% NaCl and infuse over 1-6 hours; test dose of 25 mg recommended.
Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.
None Documented
None Documented
The terminal elimination half-life is approximately 5-6 hours for the iron-dextran complex, but the iron released from the complex has a half-life of 2-3 days due to incorporation into erythrocytes and storage pools.
Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved.
Iron dextran is primarily excreted via the reticuloendothelial system; iron is incorporated into hemoglobin and stored as ferritin/ hemosiderin. Renal excretion of intact complexes is minimal (<1%). Fecal excretion accounts for less than 1% of the dose.
Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible.
Category C
Category C
Iron Replacement
Iron Replacement